Clinical trial NCT03059836: n3 PUFA and Muscle-disuse Atrophy in Young Women
Official title: Effects of n3 PUFA Supplementation on the Attenuation of Muscle Disuse Atrophy in Young Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Atrophy
Keywords: n3 PUFA
Lead sponsor: McMaster University
Sponsor class: OTHER
Collaborators: name: University of Guelph
First posted: 2017-02-23
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in women undergoing 2 weeks of unilateral limb immobilization. Assessments in skeletal muscle strength and skeletal muscle volume will also me made before, after and in recovery from immobilization.

Detailed description: Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse.

Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization.

Eligibility criteria: Inclusion Criteria:

* Female
* Aged 18-30 years

Exclusion Criteria:

* Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded
* A history of neuromuscular problems or muscle and/or bone wasting diseases
* Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires
* Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)
* Fish allergy

Primary outcomes:
measure: Muscle Volume
timeFrame: Baseline (0 days), After (14 days) of unilateral limb immobilization and at 14 days post immobilization
Secondary outcomes:
measure: Integrated Rates of Muscle Protein Synthesis
timeFrame: Before (0 days), During (0-14 days inclusive), and After (14-28 days inclusive) of unilateral limb immobilization
measure: Skeletal Muscle Strength
timeFrame: Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization
measure: Muscle Lipid Composition
timeFrame: Baseline (-28 days), and at Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: Exercise Metabolism Research Laboratory, McMaster Univeristy
state: Ontario
Study officials:
affiliation: McMaster University
name: Stuart M Phillips, PhD
role: PRINCIPAL_INVESTIGATOR
References: